Meeting
2023 ASCO Annual Meeting
Phase I study of MP0317, a FAP-dependent DARPin, for tumor-localized CD40 activation in patients with advanced solid tumors.
Authors
Carlos A. Gomez-Roca
Institut Claudius Regaud, IUCT-Oncopole, Toulouse, France
Carlos A. Gomez-Roca , Neeltje Steeghs , Eelke Hiddo Gort , Hilde A.M. De Winter , Elena Fernandez , Vaia Stavropoulou , Nina Stojcheva , Paul Baverel , Jennifer Krieg , Kyriaki Ioannou , Ana Maria Florescu , Patrick Mossi , Lea Hoenig , Bruno Baud-Berthier , Vladimir Kirkin , Anne Goubier , Philippe Legenne , Philippe Alexandre Cassier
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics—Immunotherapy
Sub Track
New Targets and New Technologies (IO)
Clinical Trial Registration Number
NCT05098405
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 2584)
DOI
10.1200/JCO.2023.41.16_suppl.2584
Abstract #
2584
Poster Bd #
426
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Annual Meeting
Dynamics of circulating cytokines and chemokines during and after tumor-infiltrating lymphocyte cell therapy with lifileucel in advanced melanoma patients.
First Author: Rongsu Qi
Poster
2022 ASCO Annual Meeting
First-in-human dose escalation and expansion study of MT-6402, a novel engineered toxin body (ETB) targeting PD-L1, in patients with PD-L1 expressing relapsed/refractory advanced solid tumors: Interim data.
First Author: Eugene R Ahn
Poster
2017 ASCO Annual Meeting
A phase I trial of the oral hedgehog inhibitor taladegib (LY2940680) in combination with weekly paclitaxel in patients with advanced, solid tumours.
First Author: Rosalind Margaret Glasspool
Poster
2017 Gastrointestinal Cancers Symposium
Biomarker studies in a phase I trial of DKN-01 in advanced esophageal cancer.
First Author: John H. Strickler